Relevant bibliographies by topics / Antipsychotic drugs

Academic literature on the topic 'Antipsychotic drugs'

Author: Grafiati
Published: 4 June 2021
Last updated: 29 July 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Antipsychotic drugs.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Antipsychotic drugs"

1

Meltzer, Herbert Y. "The Importance of Serotonin-Dopamine Interactions in the Action of Clozapine." British Journal of Psychiatry 160, S17 (May 1992): 22–29. http://dx.doi.org/10.1192/s0007125000296876.

Full text
Abstract:
Clozapine has an affinity for the dopamine (DA) D2 receptor which is relatively weak but is in line with its average clinical dose when compared with typical neuroleptic drugs. A few atypical antipsychotic drugs may have high absolute affinities for the D2 receptor, but most are weak D2 blockers. The atypical antipsychotic drugs also differ from the typical antipsychotic drugs by a relatively high affinity for the serotonin (5-HT2) receptor. This is evident on both in vitro and in vivo binding to cortical 5-HT2 receptors. The atypical antipsychotics are best distinguished from the typical antipsychotics on the basis of the relationship between strong 5-HT2 and weak D2 affinities. High D1 receptor binding is not characteristic of the group of atypical drugs. A new group of putative atypical antipsychotic drugs with high affinities for 5-HT2 compared to D2 receptors is under study.
APA, Harvard, Vancouver, ISO, and other styles
2

I Bon, Elizaveta. "The Place of Antipsychotics in the Treatment of Anxiety Disorders." Neuroscience and Neurological Surgery 14, no. 04 (June 12, 2024): 01–03. http://dx.doi.org/10.31579/2578-8868/316.

Full text
Abstract:
Antipsychotic drugs, also known as antipsychotic drugs, are used to treat a variety of mental disorders and symptoms. They are divided into two classes: first-generation, or “typical”, antipsychotics, and second-generation, or “atypical” antipsychotics. These drugs are used for a variety of neuropsychiatric conditions such as ADHD (attention deficit hyperactivity disorder), depression, insomnia, anxiety disorders, PTSD (post-traumatic stress disorder), eating disorders, personality disorders and others.
APA, Harvard, Vancouver, ISO, and other styles
3

Andriani, Yuni, Frisca Nindy Septiani, and Defirson Defirson. "Cost-effectiveness of Antipsychotics in Treatment of Schizophrenia Patients admitted to a secondary Hospital." Indonesian Journal of Pharmaceutical and Clinical Research 2, no. 2 (December 31, 2019): 43–52. http://dx.doi.org/10.32734/idjpcr.v2i2.454.

Full text
Abstract:
Abstract. Schizophrenia is a chronic disease that requires relatively high treatment costs [1]. Several studies have found that atypical antipsychotics are more effective compared to typical antipsychotics. As a result, the duration of treatment and the patients’ length of hospital stay will be shorter which ultimately reduce the overall treatment costs. Therefore, it is necessary to conduct a cost-effectiveness analysis (CEA) of the two classes of antipsychotic drugs in the treatment of schizophrenia inpatients admitted to Jambi Province Hospital period 2013-2016. Method: This descriptive retrospective cohort study was undertaken to analyze cost-effectiveness of the antipsychotic drugs provided to patients with schizophrenia (n=910) admitted to Jambi Province Hospital from the perspective of a healthcare provider. using purposive sampling technique. Characteristics of the patients, antipsychotic drugs usage, costs consumed, and treatment outcome were extracted from the hospital databases. Results: It was found that the total ACER value of the typical antipsychotic group was Rp. 142,789.25 and atypical antipsychotics is IDR 163,045.50 which indicates that the typical ACER antipsychotic value is smaller than those of atypical antipsychotics based on the length of stay of patients in the Psychiatric Intensive Care Unit (PICU) room. Whereas based on the PANSS-EC score of the patient, the total ACER value of the typical antipsychotic group was IDR1,189,910.42 and in atypical antipsychotics was IDR. 572,089.47. Conclusion: Atypical antipsychotics are more cost-effective than typical antipsychotics.
APA, Harvard, Vancouver, ISO, and other styles
4

Markowitz, John S., Barbara G. Wells, and William H. Carson. "Interactions Between Antipsychotic and Antihypertensive Drugs." Annals of Pharmacotherapy 29, no. 6 (June 1995): 603–9. http://dx.doi.org/10.1177/106002809502900610.

Full text
Abstract:
Objective: To provide a comprehensive review of the pharmacokinetic and pharmacodynamic interactions between antipsychotics and antihypertensives and to provide recommendations for the selection of antihypertensives in patients receiving antipsychotic therapy. Data Sources: A MEDLINE search of the English-language literature was used to identify pertinent human and animal studies, reviews, and case reports. Study Selection: All available sources were reviewed. Data Extraction: Background information was obtained from comprehensive reviews. Individual case reports were assimilated, and pertinent data were extracted. Data Synthesis: Because hypertension is common in patients with psychiatric illness and antihypertensive agents are used for a multiplicity of indications, significant numbers of patients receive concurrent therapy with antihypertensives and antipsychotics. Many antipsychotics may block the antihypertensive efficacy of guanethidine and related drugs. The interaction between Clonidine and antipsychotics is defined less clearly. Limited data suggest possible additive hypotensive effects when chlorpromazine and methyldopa are given in combination. Increased plasma concentrations of thioridazine with a resultant increase in adverse effects have been reported when propranolol or pindolol are added to the regimen. A similar increase in chlorpromazine concentrations has been reported when propranolol was added. Although there are no reports documenting an interaction between a calcium-channel antagonist and an antipsychotic, the possible inhibition of oxidative metabolism of antipsychotics, additive calcium-blocking activity, and additive pharmacodynamic effects are theorized. Hypotension and postural syncope were reported in a patient given therapeutic dosages of chlorpromazine and Captopril, and in 2 patients when clozapine was added to enalapril therapy. Conclusions: No antipsychotic-antihypertensive combination is absolutely contraindicated, but no combination should be considered to be completely without risk. Antihypertensives with no centrally acting activity, such as diuretics, may be the least likely to result in adverse reactions. The combination of the beta-antagonists propranolol or pindolol with thioridazine or chlorpromazine should be avoided if possible. Scrupulous patient monitoring for attenuated or enhanced activity of either agent is essential whenever antipsychotics and antihypertensives are given concurrently.
APA, Harvard, Vancouver, ISO, and other styles
5

Rybakowski, Janusz K. "Application of Antipsychotic Drugs in Mood Disorders." Brain Sciences 13, no. 3 (February 27, 2023): 414. http://dx.doi.org/10.3390/brainsci13030414.

Full text
Abstract:
Since their first application in psychiatry seventy years ago, antipsychotic drugs, besides schizophrenia, have been widely used in the treatment of mood disorders. Such an application of antipsychotics is the subject of this narrative review. Antipsychotic drugs can be arbitrarily classified into three generations. First-generation antipsychotics (FGAs), such as phenothiazines and haloperidol, were mainly applied for the treatment of acute mania, as well as psychotic depression when combined with antidepressants. The second-generation, so-called atypical antipsychotics (SGAs), such as clozapine, risperidone, olanzapine, and quetiapine, have antimanic activity and are also effective for the maintenance treatment of bipolar disorder. Additionally, quetiapine exerts therapeutic action in bipolar depression. Third-generation antipsychotics (TGAs) started with aripiprazole, a partial dopamine D2 receptor agonist, followed by brexpiprazole, lurasidone, cariprazine, and lumateperone. Out of these drugs, aripiprazole and cariprazine have antimanic activity, lurasidone, cariprazine, and lumateperone exert a significant antidepressant effect on bipolar depression, while there is evidence for the efficacy of aripiprazole and lurasidone in the prevention of recurrence in bipolar disorder. Therefore, successive generations of antipsychotic drugs present a diverse spectrum for application in mood disorders. Such a pharmacological overlap in the treatment of schizophrenia and bipolar illness stands in contrast to the dichotomous Kraepelinian division of schizophrenia and mood disorders.
APA, Harvard, Vancouver, ISO, and other styles
6

Shoja Shafti, Saeed. "Neuroleptic Malignant Syndrome: Typical Antipsychotic Drugs Versus Atypical Antipsychotic Medications." Brain and Neurological Disorders 5, no. 2 (June 21, 2022): 01–04. http://dx.doi.org/10.31579/2642-9730/025.

Full text
Abstract:
Introduction: Neuroleptic malignant syndrome is an idiosyncratic reaction and a severe disorder caused by an adverse reaction to drugs with dopamine receptor- antagonist properties and is characterized by a tetrad of rigidity, fever, altered mental status, and autonomic instability. In the present assessment, typical or conventional antipsychotics have been contrasted with atypical antipsychotics with respect to recorded cases of neuroleptic malignant syndrome among a sample of nonwestern psychiatric inpatients. Methods: For assessment, all the cases with a diagnosis of neuroleptic malignant syndrome during the last sixty-two months, after exclusion of other conceivable differential diagnoses, were incorporated in the current retrospective, record-based evaluation. The clinical diagnosis was based on the Diagnostic and Statistical Manual of Mental Disorders, 5th edition. The valuation of independent variables was analyzed by ‘Compression of proportions. Statistical significance is defined as p value ≤0.05. Results: Amongst 19814 psychiatric inpatients, in the course of sixty-two months, eighteen cases received the diagnosis of neuroleptic malignant syndrome. As said by the findings, neuroleptic malignant syndrome was meaningfully more frequent among males, in comparison with females, and it was importantly more prevalent among cases suffering from schizophrenia, in comparison with bipolar disorder. Also, the highest risk of neuroleptic malignant syndrome was found in the age group of 30-39. In the current assessment, only one of the patients, who had received haloperidol, died due to aspiration pneumonia and respiratory failure, and the most prevalent symptom was fever, which was observable in one hundred percent of cases. In addition to a similar clinical profile, ‘Compression of proportions’ did not show any significant difference between the conventional (typical) antipsychotics versus the atypical antipsychotic medications with respect to the occurrence of neuroleptic malignant syndrome. Conclusion: As said by the findings, no significant difference was evident between the typical antipsychotic drugs versus the atypical antipsychotic medications, with respect to incidence and clinical profile of neuroleptic malignant syndrome.
APA, Harvard, Vancouver, ISO, and other styles
7

Abdelmawla, Nasser, and Alex J. Mitchell. "Sudden cardiac death and antipsychotics Part 2: Monitoring and prevention." Advances in Psychiatric Treatment 12, no. 2 (March 2006): 100–109. http://dx.doi.org/10.1192/apt.12.2.100.

Full text
Abstract:
Cardiac safety of antipsychotic drugs continues to be a concern for both typical and atypical antipsychotics. Risk appears greatest in those with pre-existing cardiac disease but many patients may have occult cardiovascular disease. In addition, several drugs appear to increase the likelihood of diabetes and weight gain, which may have an additive adverse effect. On the basis of risk of sudden cardiac death and risk of QTc prolongation we suggest considering antipsychotics in two categories – higher and lower risk. Of most concern is the use of large cumulative doses of antipsychotics that are sometimes given inadvertently by different prescribers. Clinicians need to be aware how to read an ECG, and how to monitor physical parameters and interpret the significance of QTc prolongation in relation to antipsychotic prescribing. We suggest provisional guidance on antipsychotic monitoring in relation to cardiac safety but acknowledge that future studies will help clarify which antipsychotic drugs and which concomitant risk factors are most important for those with and without established cardiac disease.
APA, Harvard, Vancouver, ISO, and other styles
8

Tournier, M., A. Cougnard, B. Bégaud, A. Thiébaut, and H. Verdoux. "The Metabolic Impact of the Antipsychotic Drugs in Patients with Bipolar Disorder." European Psychiatry 24, S1 (January 2009): 1. http://dx.doi.org/10.1016/s0924-9338(09)70490-0.

Full text
Abstract:
Objective:To assess the metabolic impact of adding an antipsychotic to a mood stabilizer or switching a mood stabilizer to an antipsychotic in patients with bipolar disorder.Methods:A retrospective fixed cohort study was conducted through the claims database of the French health care program for the self-employed workers. The study population consisted of 3.172 patients age 18 and over who were exposed to mood stabilizers (i.e. lithium, valproate) a 3 month-period in 2004 without dispensing of non-sedative antipsychotic, antidiabetic or lipid-lowering drugs. The outcome was the occurrence of a metabolic incident over the follow-up period, using the dispensing of an antidiabetic drug as a marker of diabetes and the dispensing of a lipid-lowering drug as a marker of hypercholesterolemia or hypertriglyceridemia. A Cox proportional hazard model was used to assess the metabolic impact of the antipsychotics; using mood stabilizers as a reference. Antipsychotic exposition was stratified in «current» and «recent» (discontinued for less than 6 months) at the time of the metabolic incident.Results:196 patients (6.2%) received a first-generation antipsychotic, 352 (11.1%) a second-generation antipsychotic, 565 (17.8%) a sedative antipsychotic and 367 patients (11.6%) presented with a metabolic incident over the study period. The recent dispensing of a second-generation antipsychotic was associated with the occurrence of a metabolic incident [HR 2.1 (95%CI 1.2-3.7) p=0.006], while current dispensing or dispensing of first-generation antipsychotics were not.Conclusion:Second-generation antipsychotics have a metabolic impact compared to classic mood stabilizers in patients with bipolar disorder.
APA, Harvard, Vancouver, ISO, and other styles
9

El-Khayat, Redwan, and David S. Baldwin. "Antipsychotic drugs for non-psychotic patients." Psychiatric Bulletin 23, no. 7 (July 1999): 416–18. http://dx.doi.org/10.1192/pb.23.7.416.

Full text
Abstract:
Aims and methodThe aim of this study was to examine the pattern and basis of use of psychotropic drug prescriptions by psychiatrists to relieve anxiety symptoms arising from non-psychotic disorders. A questionnaire survey was conducted among senior psychiatrists in the Wessex region.ResultsThe response rate was 74%. A range of psychotropic drugs was used to treat non-psychotic anxiety symptoms, most commonly selective serotonin re-uptake inhibitors, tricyclic antidepressants and antipsychotic drugs. Antipsychotic drugs are reserved for second- and third-line treatments, mainly in low doses but sometimes in high doses and for long periods. The use of antipsychotic drugs as anxiolytics was seen by the majority of responders as reasonable practice, and they are considered suitable alternatives to benzodiazepines. This practice was based mainly on personal experience.Clinical implicationsAnxiety symptoms arising from non-psychotic disorders are common in the out-patient population. Although antipsychotics are used by psychiatrists to relieve these symptoms, the ‘evidence base’ for such practice is flimsy and mainly based on clinical experience. The benefit/risk ratio should be considered carefully before prescribing antipsychotics for non-psychotic anxiety. Further research is needed in this area, contributing towards general guidelines.
APA, Harvard, Vancouver, ISO, and other styles
10

Grundmann, Milan, Ivana Kacirova, and Romana Urinovska. "Therapeutic drug monitoring of atypical antipsychotic drugs." Acta Pharmaceutica 64, no. 4 (December 1, 2014): 387–401. http://dx.doi.org/10.2478/acph-2014-0036.

Full text
Abstract:
Abstract Schizophrenia is a severe psychiatric disorder often associated with cognitive impairment and affective, mainly depressive, symptoms. Antipsychotic medication is the primary intervention for stabilization of acute psychotic episodes and prevention of recurrences and relapses in patients with schizophrenia. Typical antipsychotics, the older class of antipsychotic agents, are currently used much less frequently than newer atypical antipsychotics. Therapeutic drug monitoring (TDM) of antipsychotic drugs is the specific method of clinical pharmacology, which involves measurement of drug serum concentrations followed by interpretation and good cooperation with the clinician. TDM is a powerful tool that allows tailor-made treatment for the specific needs of individual patients. It can help in monitoring adherence, dose adjustment, minimizing the risk of toxicity and in cost-effectiveness in the treatment of psychiatric disorders. The review provides complex knowledge indispensable to clinical pharmacologists, pharmacists and clinicians for interpretation of TDM results.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Antipsychotic drugs"

1

Mahmoud, Ahmed Mohamed. "Antipsychotic drugs and sexual function in schizophrenia." Thesis, University of Manchester, 2008. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.493418.

Full text
Abstract:
Sexual function is an important aspect of human experience and may significantly contribute to quality of life. For patients with schizophrenia, the impact of the antipsychotic drugs on sexual functions is an area to be researched. Most of the newer antipsychotic drugs have a different mood of action which is believed to account for the low incidence of extra pyramidal side effects and hyperprolactinemia.
APA, Harvard, Vancouver, ISO, and other styles
2

Melkersson, Kristina. "Influence of antipsychotic drugs on hormone levels /." Stockholm, 2000. http://diss.kib.ki.se/2000/91-628-4089-4/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Duncan, Carlotta Clinical School St Vincent's Hospital Faculty of Medicine UNSW. "Molecular expression analyses of mice treated with antipsychotic drugs." Publisher:University of New South Wales. Clinical School - St Vincent's Hospital, 2008. http://handle.unsw.edu.au/1959.4/41239.

Full text
Abstract:
Schizophrenia is a devastating psychiatric disorder that affects approximately 1% of the population. The main treatments for schizophrenia are antipsychotic drugs that target dopamine receptors, yet the underlying biological mechanisms through which they alleviate the symptoms of schizophrenia remain ill defined. In this study, we used microarray analysis to profile the expression changes of thousands of genes simultaneously, following antipsychotic drug treatment of mice. Mice were treated chronically (28 days), or for a novel intermediate time-point (7 days), with one of three antipsychotic drugs: clozapine, haloperidol or olanzapine. The use of three drugs enabled us to discern antipsychotic-specific effects co-regulated by multiple drugs, rather than the side effects of individual compounds. Transcript profiling and validation by quantitative PCR of whole brain tissue revealed antipsychotic drug regulation of genes in diverse biological pathways, including: dopamine metabolism, neuropeptide and second-messenger signalling, neurogenesis, synaptic plasticity, cell adhesion, myelination, and voltage-gated ion channels. The regulation of voltage-gated channels by antipsychotic drugs has been suggested previously by electrophysiological studies, although thorough analysis has not been undertaken in vivo. Therefore, the second aim of this study was to characterise the regional mRNA and protein expression of two genes altered by multiple APDs, the voltage-gated potassium channel ??-subunit (Kcna1) and voltage-gated potassium channel interacting protein (Kchip3). Regional characterisation and expression analyses were carried out by immunohistochemistry, in situ hybridisation, and Western blot analysis of mouse brain regions of interest to schizophrenia and its treatment. Following 7-day haloperidol treatment we observed up-regulation of Kcna1 in the striatum and dentate gyrus, with increased protein in the striatum, hippocampus and midbrain; and down-regulation of Kchip3 in the striatum, with decreased protein in the cortex, hippocampus and midbrain. These studies implicate voltage-gated potassium channels in the antipsychotic drug regulation of midbrain dopaminergic neuronal activity, adult neurogenesis and/or striatothalamic GABAergic neuronal inhibition. These findings indicate that regulation of potassium channels may underlie some of the mechanisms of action of antipsychotic drugs, and that voltage-gated ion channels may provide alternative drug targets for the treatment of schizophrenia.
APA, Harvard, Vancouver, ISO, and other styles
4

Grottick, Andrew John. "The temporal effects of typical and atypical antipsychotic drugs." Thesis, London Metropolitan University, 1998. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.297507.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Tuninger, Eva. "Depot neuroleptic maintenance treatment clinical, pharmacological and neuropsychological aspects /." Lund : Dept. of Psychiatry, Lund University, University Hospital MAS, 1997. http://catalog.hathitrust.org/api/volumes/oclc/40281424.html.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Rudissaar, Ruth. "Neuropharmacology of atypical antipsychotics and an animal model of psychosis /." Online version, 2006. http://dspace.utlib.ee/dspace/bitstream/10062/1294/5/rudissaarruth.pdf.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

王漪雯 and Belinda Wong. "Haloperidol metabolism in man and animals." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 1993. http://hub.hku.hk/bib/B3121194X.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Mobini, Sirous. "Behavioural analysis of the roles of the ascending monoaminergic pathways and the orbitofrontal cortex in impulse control and motivation." Thesis, University of Nottingham, 2001. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.368261.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

D'Souza, Ursula M. "Structure of the D←2 dopamine receptor." Thesis, University of Kent, 1994. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.259680.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Furmidge, Lesley Jane. "Effects of partial dopamine D2 agonists on d-amphetamine-induced behaviour." Thesis, University of Reading, 1990. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.280506.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Antipsychotic drugs"

1

Y, Meltzer Herbert, ed. Novel antipsychotic drugs. New York: Raven Press, 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Davantzis, C. J. Antipsychotic agents. Cypress, Calif: Medcom, 2005.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

E, Barnes Thomas R., ed. Antipsychotic drugs and their side-effects. London: Academic Press, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

J, Sramek John, ed. Optimizing the development of antipsychotic drugs. Chichester: John Wiley & Sons, 1997.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Connelly, Peter J. Are antipsychotic drugs usedappropriately in geriatric psychiatry? (Edinburgh): Scottish Office, 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

D, Burrows Graham, Norman Trevor R. 1946-, and Davies Brian 1928-, eds. Antipsychotics. Amsterdam: Elsevier, 1985.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Laurence, Mignon, ed. Stahl's illustrated antipsychotics: Treating psychosis, mania, and depression. 2nd ed. Cambridge: Cambridge University Press, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

1960-, Stroup T. Scott, and Lieberman Jeffrey A. 1948-, eds. Antipsychotic trials in schizophrenia: The CATIE project. Cambridge: Cambridge University Press, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Rothschild, Anthony J. The evidence-based guide to antipsychotic medications. Washington, DC: American Psychiatric Pub., 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

S, Lidow Michael, ed. Neurotransmitter receptors in actions of antipsychotic medications. Boca Raton: CRC Press, 2000.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Antipsychotic drugs"

1

Scherrmann, Jean-Michel, Kim Wolff, Christine A. Franco, Marc N. Potenza, Tayfun Uzbay, Lisiane Bizarro, David C. S. Roberts, et al. "Antipsychotic Drugs." In Encyclopedia of Psychopharmacology, 118–22. Berlin, Heidelberg: Springer Berlin Heidelberg, 2010. http://dx.doi.org/10.1007/978-3-540-68706-1_242.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Scherrmann, Jean-Michel, Kim Wolff, Christine A. Franco, Marc N. Potenza, Tayfun Uzbay, Lisiane Bizarro, David C. S. Roberts, et al. "Antipsychotic Drugs." In Encyclopedia of Psychopharmacology, 115. Berlin, Heidelberg: Springer Berlin Heidelberg, 2010. http://dx.doi.org/10.1007/978-3-540-68706-1_3061.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Miyamoto, Seiya, David B. Merrill, Jeffrey A. Lieberman, W. Wolfgang Fleischacker, and Stephen R. Marder. "Antipsychotic Drugs." In Psychiatry, 2161–201. Chichester, UK: John Wiley & Sons, Ltd, 2008. http://dx.doi.org/10.1002/9780470515167.ch102.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Fleischhacker, W. Wolfgang, and Seiya Miyamoto. "Antipsychotic Drugs." In Encyclopedia of Psychopharmacology, 153–58. Berlin, Heidelberg: Springer Berlin Heidelberg, 2015. http://dx.doi.org/10.1007/978-3-642-36172-2_242.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Miyamoto, Seiya, David B. Merrill, L. Fredrik Jarskog, W. Wolfgang Fleishhacker, Stephen R. Marder, and Jeffrey A. Lieberman. "Antipsychotic Drugs." In Psychiatry, 2088–128. Chichester, UK: John Wiley & Sons, Ltd, 2015. http://dx.doi.org/10.1002/9781118753378.ch104.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Kaur, Harleen, Ramneek Kaur, Varsha Rani, Kanishka Sharma, and Pawan Kumar Maurya. "Antipsychotic Drugs." In Advances in Neuropharmacology, 297–316. Includes bibliographical references and index.: Apple Academic Press, 2020. http://dx.doi.org/10.1201/9780429242717-15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Fleischhacker, W. Wolfgang, and Seiya Miyamoto. "Antipsychotic Drugs." In Encyclopedia of Psychopharmacology, 1–7. Berlin, Heidelberg: Springer Berlin Heidelberg, 2013. http://dx.doi.org/10.1007/978-3-642-27772-6_242-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Kshirsagar, Sarang Naresh, and Tapas Kumar Sahoo. "Antipsychotic Drugs." In Principles and Practice of Neurocritical Care, 355–63. Singapore: Springer Nature Singapore, 2024. http://dx.doi.org/10.1007/978-981-99-8059-8_25.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Scherrmann, Jean-Michel, Kim Wolff, Christine A. Franco, Marc N. Potenza, Tayfun Uzbay, Lisiane Bizarro, David C. S. Roberts, et al. "Atypical Antipsychotic Drugs." In Encyclopedia of Psychopharmacology, 182. Berlin, Heidelberg: Springer Berlin Heidelberg, 2010. http://dx.doi.org/10.1007/978-3-540-68706-1_468.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Blows, William T. "The antipsychotic drugs." In The Biological Basis of Mental Health, 284–93. 4th ed. London: Routledge, 2021. http://dx.doi.org/10.4324/9781003097273-16.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Antipsychotic drugs"

1

VANELLE, J. M., M. F. POIRIER, A. GALINOWSKI, and H. LÔO. "NEW ANTIPSYCHOTIC DRUGS IN SCHIZOPHRENIA: FRENCH EXPERIENCE AND PERSPECTIVES." In IX World Congress of Psychiatry. WORLD SCIENTIFIC, 1994. http://dx.doi.org/10.1142/9789814440912_0214.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Ferreira, Maria, Ana Cláudia Paiva-Santos, Francisco Veiga, and Patrícia C. Pires. "The Importance of Nanosystems in Antipsychotic Drugs Brain Targeting." In ASEC 2022. Basel Switzerland: MDPI, 2022. http://dx.doi.org/10.3390/asec2022-13765.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Thanontip, Kamonwan, Banthit Chetsawang, and Vasunun Chumchua. "Novel Protein-Protein Interaction Network of Antipsychotic Drugs and Cognitive Function." In 2019 12th Biomedical Engineering International Conference (BMEiCON). IEEE, 2019. http://dx.doi.org/10.1109/bmeicon47515.2019.8990302.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Sun, Jingchun, and Zhongming Zhao. "Pathway-assisted investigation of atypical antipsychotic drugs and serotonin receptors in schizophrenia." In 2010 Biomedical Sciences and Engineering Conference (BSEC). IEEE, 2010. http://dx.doi.org/10.1109/bsec.2010.5510845.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Castillejo, R., LDL Rueda Bermudez, G. Ramirez Soto, N. Rebollo Diaz, and Á. López Díaz. "4CPS-198 Analysis of antipsychotic drugs use at a Spanish tertiary hospital." In 27th EAHP Congress, Lisbon, Portugal, 22-23-24 March 2023. British Medical Journal Publishing Group, 2023. http://dx.doi.org/10.1136/ejhpharm-2023-eahp.188.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

ELKIS, HELIO, LEE FRIEDMAN, CHRISTINE LYS, HERBERT Y. MELTZER, and DOUGLAS D. BOND. "RELATIONSHIP BETWEEN POSITIVE AND NEGATIVE SYMPTOMS: RESPONSE TO ANTIPSYCHOTIC DRUGS AND STRUCTURAL BRAIN ABNORMALITIES." In IX World Congress of Psychiatry. WORLD SCIENTIFIC, 1994. http://dx.doi.org/10.1142/9789814440912_0089.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Morais e Coura, Carla Patricia de, and Viviane Muniz da Silva Fragoso. "Using the fluorescence quenching model to compare the plasmatic transport of two antipsychotic drugs by serum albumin." In INTERNATIONAL CONFERENCE OF COMPUTATIONAL METHODS IN SCIENCES AND ENGINEERING 2014 (ICCMSE 2014). AIP Publishing LLC, 2014. http://dx.doi.org/10.1063/1.4897811.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Zhao, Zhongming. "5.7: Presentation session: Neuroscience informatics: “Pathway-assisted investigation of atypical antipsychotic drugs and serotonin receptors in schizophrenia”." In 2010 Biomedical Sciences and Engineering Conference (BSEC). IEEE, 2010. http://dx.doi.org/10.1109/bsec.2010.5510846.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Claassen, Daniel, Hela Romdhani, Rajeev Ayyagari, Debbie Goldschmidt, Sarah Moroz, Adreanna Hernandez, Nayla Chaijale, and Sam Leo. "Real-World Effectiveness and Safety of Deutetrabenazine in Combination with Antipsychotic Drugs in Patients With Chorea Associated With Huntington Disease (P2-11.010)." In 2023 Annual Meeting Abstracts. Lippincott Williams & Wilkins, 2023. http://dx.doi.org/10.1212/wnl.0000000000201971.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Lozano López, María Teresa, Sinta Gamonal Limcaoco, Nerea M. Casado Espada, Ana Macia Casas, Alberto Bullon Saez, Marina Covacho Gonzalez, Alba Gonzalez Mota, et al. "SYSTEMATIC REVIEW OF THE OCCURRENCE OF PSYCHOTIC SYMPTOMS IN THE TRAMADOL AND OXYCODONE WITHDRAWAL ." In 22° Congreso de la Sociedad Española de Patología Dual (SEPD) 2020. SEPD, 2020. http://dx.doi.org/10.17579/sepd2020p038.

Full text
Abstract:
Objetives: To begin with, this systematic review arises from the interest to know about the appearance of psychotic and opioid symptomatology. Therefore, the main objective of this research is to establish the appearance of psychotic symptoms in the removal of oxycodone and tramadol. Methods: As far as the research procedure is concerned, a systematic review has been carried out which focuses on the relation of the psychotic symptoms caused by the withdrawal of buprenorphine. In this way, we have selected those scientific papers filed in the database PubMed looking for the key words: “Tramadol; Oxycodone” AND “psychosis, psychotic symptoms; schizophrenia”. Results and conclusions: In current literature, there are three publications dealing with clinic cases where patients suffered from psychotic symptoms after the removal of tramadol or oxycodone. Two of them are case reports about patients who presented psychotic symptoms after stopping these opioids. It is necessary to continue observing and reporting all cases of psychotic symptoms after an opioid withdrawal, as well as the potential antipsychotic effect of the drugs
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Antipsychotic drugs"

1

Liu, Liangshuai, Heping Li, Guosheng Tan, and Zhenjiang Ma. Traditional Chinese Herbal Medicine in Treating Amenorrhea Caused by Antipsychotic Drugs: Meta-analysis and systematic review. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, May 2021. http://dx.doi.org/10.37766/inplasy2021.5.0009.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Merino, Diane, Arnaud Fernandez, Alexandre Gérard, Nouha Ben Othman, Fanny Rocher, Florence Askenazy, Céline Verstuyft, Milou-Daniel Drici, and Susanne Thümmler. Protocol: Adverse Drug Reactions of Olanzapine, Clozapine and Loxapine in Children and Youth: A Systematic Pharmacogenetic Review. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, May 2022. http://dx.doi.org/10.37766/inplasy2022.5.0025.

Full text
Abstract:
Review question / Objective: In children and youth treated with olanzapine, clozapine, or loxapine and having undergone genotyping, which are the pharmacogenetic variants underlying the antipsychotics' adverse drug reactions and efficacy? What are the most frequently investigated adverse drug reactions and variants ? What is described about the specific effect of CYP1A2 variants ? Therefore, we aimed to review the pharmacogenetic variants underlying olanzapine, clozapine and loxapine ADRs and/or efficacy, in children and youth having undergone genotyping. Then, assessed the most frequently investigated ADRs and genetic polymorphisms in this population. Finally, we investigated the specific effect of CYP1A2 variants in the occurrence of ADRs and/or lack of therapeutic effect. Condition being studied: This review focuses on children, adolescents and youth treated with antipsychotics (olanzapine, clozapine, loxapine) and experienced adverse drug reactions.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Antipsychotic drugs' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography